fluoxetine has been researched along with Incipient Schizophrenia in 3 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-two patients meeting the criteria for borderline or schizotypal personality disorder or both participated in a prospective, nonblind 12-week trial of fluoxetine." | 9.07 | Fluoxetine in the treatment of borderline and schizotypal personality disorders. ( Calabrese, JR; Markovitz, PJ; Meltzer, HY; Schulz, SC, 1991) |
| "Twenty-two patients meeting the criteria for borderline or schizotypal personality disorder or both participated in a prospective, nonblind 12-week trial of fluoxetine." | 5.07 | Fluoxetine in the treatment of borderline and schizotypal personality disorders. ( Calabrese, JR; Markovitz, PJ; Meltzer, HY; Schulz, SC, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mulder, RT | 1 |
| Frampton, CM | 1 |
| Luty, SE | 1 |
| Joyce, PR | 1 |
| Ravizza, L | 1 |
| Barzega, G | 1 |
| Bellino, S | 1 |
| Bogetto, F | 1 |
| Maina, G | 1 |
| Markovitz, PJ | 1 |
| Calabrese, JR | 1 |
| Schulz, SC | 1 |
| Meltzer, HY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical, Neurocognitive and Neuroimaging Variables Associated With Response to Treatment in Patients With OCD[NCT03993535] | Phase 4 | 250 participants (Actual) | Interventional | 2018-10-10 | Active, not recruiting | ||
| An Open-Label Trial of Epidiolex in the Treatment of Obsessive Compulsive Disorder and Related Disorders: Proof of Concept Study[NCT04978428] | Phase 2 | 15 participants (Anticipated) | Interventional | 2022-04-14 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for fluoxetine and Incipient Schizophrenia
| Article | Year |
|---|---|
Eighteen months of drug treatment for depression: predicting relapse and recovery.
Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents; Depressive Disorder; Dose-Response R | 2009 |
Predictors of drug treatment response in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Age of Onset; Clomipramine; Comorbidity; Fluoxetine; Follow-Up Studies; Humans; M | 1995 |
Predictors of drug treatment response in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Age of Onset; Clomipramine; Comorbidity; Fluoxetine; Follow-Up Studies; Humans; M | 1995 |
Predictors of drug treatment response in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Age of Onset; Clomipramine; Comorbidity; Fluoxetine; Follow-Up Studies; Humans; M | 1995 |
Predictors of drug treatment response in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Age of Onset; Clomipramine; Comorbidity; Fluoxetine; Follow-Up Studies; Humans; M | 1995 |
Fluoxetine in the treatment of borderline and schizotypal personality disorders.
Topics: Adult; Borderline Personality Disorder; Chronic Disease; Drug Administration Schedule; Female; Fluox | 1991 |